Cytosorbents (NASDAQ:CTSO) Coverage Initiated at StockNews.com

StockNews.com assumed coverage on shares of Cytosorbents (NASDAQ:CTSO - Free Report) in a research note published on Wednesday morning. The brokerage issued a hold rating on the medical research company's stock.

Separately, D. Boral Capital reaffirmed a "buy" rating and set a $10.00 target price on shares of Cytosorbents in a research report on Tuesday, February 25th. Two analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Cytosorbents presently has a consensus rating of "Moderate Buy" and a consensus price target of $4.67.

Cytosorbents Stock Performance

NASDAQ CTSO remained flat at $1.00 on Wednesday. 47,649 shares of the company's stock traded hands, compared to its average volume of 145,125. The company has a quick ratio of 1.58, a current ratio of 1.97 and a debt-to-equity ratio of 1.06. Cytosorbents has a 52 week low of $0.70 and a 52 week high of $1.61. The stock has a market capitalization of $54.68 million, a price-to-earnings ratio of -2.78 and a beta of 0.78. The business has a 50-day moving average price of $1.07 and a two-hundred day moving average price of $1.05.

Remove Ads

Institutional Trading of Cytosorbents

A number of hedge funds have recently added to or reduced their stakes in the business. Avenir Corp increased its position in Cytosorbents by 4.0% during the 4th quarter. Avenir Corp now owns 3,093,946 shares of the medical research company's stock valued at $2,815,000 after purchasing an additional 118,387 shares during the period. Skylands Capital LLC increased its holdings in Cytosorbents by 1.0% during the fourth quarter. Skylands Capital LLC now owns 2,781,622 shares of the medical research company's stock valued at $2,531,000 after buying an additional 26,195 shares during the period. Geode Capital Management LLC increased its holdings in Cytosorbents by 7.5% during the third quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company's stock valued at $701,000 after buying an additional 32,415 shares during the period. Raymond James Financial Inc. bought a new position in Cytosorbents in the fourth quarter worth approximately $99,000. Finally, Northern Trust Corp lifted its holdings in Cytosorbents by 22.3% during the fourth quarter. Northern Trust Corp now owns 91,560 shares of the medical research company's stock worth $83,000 after buying an additional 16,701 shares during the period. 32.87% of the stock is owned by hedge funds and other institutional investors.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.